Lancet 395, 1845–1854 (2020)
The urgent need to develop a vaccine against SARs-CoV2 compressed the normal vaccine-development timeline to reach in-human clinical trials from several years to just over two months, and a vaccine developed by Moderna was the first to reach this stage in March.
In late May, CanSino Biologics was the first to publish their trial results of a vaccine against COVID-19 in a peer-reviewed journal. CanSino’s candidate is an adenoviral construct that expresses the SARS-CoV-2 spike glycoprotein. It was found to be immunogenic, with most of the 108 participants developing specific antibody and T cell responses. Although 81% of the immunized participants reported moderate adverse effects, no serious adverse reactions occurred. So far, no conclusive information on efficacy is available for CanSino’s, or any other, vaccine candidate.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carvalho, T. Vaccines in the fast lane. Nat Med 26, 1807 (2020). https://doi.org/10.1038/s41591-020-01167-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-01167-8